Australian clinical-stage company Immutep has announced positive data from the INSIGHT-003 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer. …
Australian company says 'Efti' INSIGHT-003 lung cancer trial reveals positive survival data
November 14, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 29 August
August 29, 2025 - - Podcast -
Government pressed on diabetes inquiry response as obesity costs soar
August 29, 2025 - - Latest News -
NDIS quarterly report presents a positive picture, but questions remain
August 29, 2025 - - Latest News -
Wesfarmers Health delivers growth as Priceline drives consumer momentum
August 29, 2025 - - Latest News -
'We can evade reality, but we cannot evade the consequences of evading reality'
August 29, 2025 - - Latest News -
Australians fear the loss of independence as vision health concerns rise
August 29, 2025 - - Latest News -
Coalition turns debate on cheaper medicines Bill to HTA reform delays
August 27, 2025 - - Latest News